Corbus Pharmaceuticals Holdings, Inc. (CRBP): Price and Financial Metrics

Corbus Pharmaceuticals Holdings, Inc. (CRBP): $1.02

-0.01 (-0.49%)

POWR Rating

Component Grades













Add CRBP to Watchlist
Sign Up

Industry: Biotech


of 506

in industry


  • CRBP scores best on the Growth dimension, with a Growth rank ahead of 83.24% of US stocks.
  • CRBP's strongest trending metric is Quality; it's been moving up over the last 47 weeks.
  • CRBP ranks lowest in Momentum; there it ranks in the 4th percentile.

CRBP Stock Summary

  • With a year-over-year growth in debt of 203.61%, Corbus Pharmaceuticals Holdings Inc's debt growth rate surpasses 95.67% of about US stocks.
  • As for revenue growth, note that CRBP's revenue has grown -62.93% over the past 12 months; that beats the revenue growth of merely 3.27% of US companies in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for CRBP comes in at -94.36% -- higher than that of just 2.24% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Corbus Pharmaceuticals Holdings Inc are PRQR, GLYC, MTEM, MEIP, and ZYME.
  • CRBP's SEC filings can be seen here. And to visit Corbus Pharmaceuticals Holdings Inc's official web site, go to

CRBP Valuation Summary

  • In comparison to the median Healthcare stock, CRBP's price/sales ratio is 432.16% higher, now standing at 60.4.
  • CRBP's price/sales ratio has moved NA NA over the prior 83 months.
  • CRBP's price/earnings ratio has moved up 46.2 over the prior 83 months.

Below are key valuation metrics over time for CRBP.

Stock Date P/S P/B P/E EV/EBIT
CRBP 2021-08-31 60.4 2.1 -2.1 -2.0
CRBP 2021-08-30 55.7 1.9 -1.9 -1.9
CRBP 2021-08-27 58.1 2.0 -2.0 -1.9
CRBP 2021-08-26 56.7 2.0 -2.0 -1.9
CRBP 2021-08-25 58.5 2.0 -2.0 -2.0
CRBP 2021-08-24 60.0 2.1 -2.1 -2.0

CRBP Growth Metrics

  • The year over year price growth rate now stands at -79.07%.
  • The year over year net income to common stockholders growth rate now stands at -30.45%.
  • The 3 year net income to common stockholders growth rate now stands at -587.86%.
CRBP's revenue has moved down $221,759 over the prior 33 months.

The table below shows CRBP's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 2.673207 -84.8155 -76.7108
2021-03-31 2.822995 -93.89405 -97.67775
2020-12-31 3.93723 -99.6857 -111.2694
2020-09-30 5.852546 -104.0233 -129.2382
2020-06-30 7.211708 -93.85688 -115.1337
2020-06-30 7.211708 -93.85688 -115.1337

CRBP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CRBP has a Quality Grade of C, ranking ahead of 46.81% of graded US stocks.
  • CRBP's asset turnover comes in at 0.023 -- ranking 366th of 677 Pharmaceutical Products stocks.
  • ARNA, ARWR, and MRSN are the stocks whose asset turnover ratios are most correlated with CRBP.

The table below shows CRBP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.023 1 -1.703
2021-03-31 0.026 1 -4.511
2020-12-31 0.044 1 -168.104
2020-09-30 0.076 1 31.788
2020-06-30 0.103 1 20.133
2020-06-30 0.103 1 20.133

CRBP Price Target

For more insight on analysts targets of CRBP, see our CRBP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $1.88 Average Broker Recommendation 1.92 (Hold)

CRBP Stock Price Chart Interactive Chart >

Price chart for CRBP

CRBP Price/Volume Stats

Current price $1.02 52-week high $4.00
Prev. close $1.02 52-week low $0.91
Day low $1.00 Volume 1,558,793
Day high $1.07 Avg. volume 6,518,022
50-day MA $1.31 Dividend yield N/A
200-day MA $1.77 Market Cap 127.11M

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Company Bio

Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. The company is based in Norwood, Massachusetts.

CRBP Latest News Stream

Event/Time News Detail
Loading, please wait...

CRBP Latest Social Stream

Loading social stream, please wait...

View Full CRBP Social Stream

Latest CRBP News From Around the Web

Below are the latest news stories about Corbus Pharmaceuticals Holdings Inc that investors may wish to consider to help them evaluate CRBP as an investment opportunity.

Could The Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Ownership Structure Tell Us Something Useful?

The big shareholder groups in Corbus Pharmaceuticals Holdings, Inc. ( NASDAQ:CRBP ) have power over the company...

Yahoo | September 10, 2021

Arena Pharma, GrowGen & HEXO Among Top Cannabis Stock Movers On August 23, 2021

GAINERS: iAnthus Capital Hldgs (OTC: ITHUF ) shares closed up 35.27% at $0.28 with an estimated market cap of $48,870,997. Aleafia Health (OTC: ALEAF ) shares closed up 18.23% at $0.27 with an estimated market cap of $89,868,989. Item 9 Labs (OTC: INLB ) shares closed up 17.65% at $2 with an estimated market cap of $184,419,042. Tetra Bio Pharma (OTC: TBPMF ) shares closed up 10.78% at $0.24 with an estimated market cap of $96,530,242. Neptune Wellness Solns (NASDAQ: NEPT ) shares closed up 9.76% at $0.66 with an estimated market cap of $110,369,189. HEXO (NYSE: HEXO ) shares closed up 9.7% at $2.55 with an estimated market cap of $387,927,112. Arena Pharmaceuticals (NASDAQ: ARNA ) shares closed up 9.19% at $51.21 with an estimated market cap of $3,127,620,843. Urban-gro (NASDAQ: UGRO )...

Benzinga | August 23, 2021

Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates

Norwood, MA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (Corbus or the Company), an immunology company, today provided corporate updates and reported financial results for the second quarter of 2021.

Intrado Digital Media | August 12, 2021

Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -25.00% and -83.57%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 12, 2021

Global Cannabis Pharmaceutical Market Booming At A CAGR Of 56.5% By 2028 Top Key Players Bausch Health Companies Inc., AbbVie Inc., Insys Therapeutics, Inc., Corbus Pharmaceuticals Holdings, Inc., Teva Pharmaceutical Industries Ltd

According to Data Bridge Market Research, Cannabis Pharmaceutical Market provides a comprehensive analysis of the Cannabis Pharmaceutical Market segments, including their dynamics, size, growth, regulatory requirements, competitive landscape, and emerging opportunities of global industry.This report also provides market landscape and

OpenPR | August 11, 2021

Read More 'CRBP' Stories Here

CRBP Price Returns

1-mo -10.53%
3-mo -47.42%
6-mo -49.25%
1-year -46.32%
3-year -85.32%
5-year -86.25%
YTD -18.40%
2020 -77.11%
2019 -6.51%
2018 -17.75%
2017 -15.98%
2016 412.12%

Continue Researching CRBP

Here are a few links from around the web to help you further your research on Corbus Pharmaceuticals Holdings Inc's stock as an investment opportunity:

Corbus Pharmaceuticals Holdings Inc (CRBP) Stock Price | Nasdaq
Corbus Pharmaceuticals Holdings Inc (CRBP) Stock Quote, History and News - Yahoo Finance
Corbus Pharmaceuticals Holdings Inc (CRBP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7925 seconds.